{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:44:54Z","timestamp":1793328294815,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52072005"],"award-info":[{"award-number":["52072005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["51872279"],"award-info":[{"award-number":["51872279"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.tranon.2022.101441","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T05:52:43Z","timestamp":1651557163000},"page":"101441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["ALYREF associated with immune infiltration is a prognostic biomarker in hepatocellular carcinoma"],"prefix":"10.1016","volume":"21","author":[{"given":"Zhen-Zhen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Qi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-4055","authenticated-orcid":false,"given":"Li-Xin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tranon.2022.101441_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.tranon.2022.101441_bib0002","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"4","key":"10.1016\/j.tranon.2022.101441_bib0003","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/hep.30633","article-title":"Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy","volume":"70","author":"Brown","year":"2019","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.tranon.2022.101441_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102859","article-title":"Immunotherapy for hepatocellular carcinoma: a 2021 update","volume":"12","author":"Kole","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2022.101441_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.568759","article-title":"Combinational immunotherapy for hepatocellular carcinoma: radiotherapy, immune checkpoint blockade and beyond","volume":"11","author":"Lee","year":"2020","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.tranon.2022.101441_bib0006","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201899910","article-title":"ALYREF links 3\u2032-end processing to nuclear export of non-polyadenylated mRNAs","volume":"38","author":"Fan","year":"2019","journal-title":"EMBO J."},{"issue":"7721","key":"10.1016\/j.tranon.2022.101441_bib0007","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41586-018-0453-z","article-title":"The NORAD lncRNA assembles a topoisomerase complex critical for genome stability","volume":"561","author":"Munschauer","year":"2018","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.tranon.2022.101441_bib0008","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/cac2.12158","article-title":"The role of the HIF-1alpha\/ALYREF\/PKM2 axis in glycolysis and tumorigenesis of bladder cancer","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun."},{"issue":"1","key":"10.1016\/j.tranon.2022.101441_bib0009","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/s41467-021-22143-x","article-title":"An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability","volume":"12","author":"Nagy","year":"2021","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.tranon.2022.101441_bib0010","first-page":"6841","article-title":"Gene signatures of m5C regulators may predict prognoses of patients with head and neck squamous cell carcinoma","volume":"12","author":"Xue","year":"2020","journal-title":"Am. J. Transl. Res."},{"issue":"4","key":"10.1016\/j.tranon.2022.101441_bib0011","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00432-012-1361-5","article-title":"ALY as a potential contributor to metastasis in human oral squamous cell carcinoma","volume":"139","author":"Saito","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.tranon.2022.101441_bib0012","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/OTT.S286408","article-title":"ALYREF drives cancer cell proliferation through an ALYREF-MYC positive feedback loop in glioblastoma","volume":"14","author":"Wang","year":"2021","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.tranon.2022.101441_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.633415","article-title":"Multi-omic analyses of the m(5)c regulator ALYREF reveal its essential roles in hepatocellular carcinoma","volume":"11","author":"Xue","year":"2021","journal-title":"Front. Oncol."},{"issue":"21","key":"10.1016\/j.tranon.2022.101441_bib0014","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2022.101441_bib0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/2326-6066.CIR-17-0201","article-title":"Impact of tumor purity on immune gene expression and clustering analyses across multiple cancer types","volume":"6","author":"Rhee","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"8","key":"10.1016\/j.tranon.2022.101441_bib0016","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","article-title":"How to build and interpret a nomogram for cancer prognosis","volume":"26","author":"Iasonos","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2022.101441_bib0017","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.tranon.2022.101441_bib0018","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3389\/fmed.2020.00451","article-title":"Evaluating distribution and prognostic value of new tumor-infiltrating lymphocytes in HCC based on a scRNA-seq study with CIBERSORTx","volume":"7","author":"Li","year":"2020","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.tranon.2022.101441_bib0019","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.gendis.2020.01.014","article-title":"Advances in the early diagnosis of hepatocellular carcinoma","volume":"7","author":"Wang","year":"2020","journal-title":"Genes Dis."},{"issue":"12","key":"10.1016\/j.tranon.2022.101441_bib0020","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","article-title":"Immunological landscape and immunotherapy of hepatocellular carcinoma","volume":"12","author":"Prieto","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.tranon.2022.101441_bib0021","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-17-0289","article-title":"Immunotherapy of hepatocellular carcinoma: facts and hopes","volume":"24","author":"Inarrairaegui","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101441_bib0022","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","article-title":"DNA replication stress as a hallmark of cancer","volume":"10","author":"Macheret","year":"2015","journal-title":"Ann. Rev. Pathol."},{"issue":"3","key":"10.1016\/j.tranon.2022.101441_bib0023","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tcb.2008.12.003","article-title":"Cell-cycle control in the face of damage\u2013a matter of life or death","volume":"19","author":"Clarke","year":"2009","journal-title":"Trends Cell Biol."},{"issue":"1","key":"10.1016\/j.tranon.2022.101441_bib0024","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s13046-019-1396-4","article-title":"From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma","volume":"38","author":"Fu","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.tranon.2022.101441_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrgastro.2015.200","article-title":"Immunology in the liver-from homeostasis to disease","volume":"13","author":"Heymann","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tranon.2022.101441_bib0026","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.biopha.2017.08.003","article-title":"The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer","volume":"95","author":"Liu","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.tranon.2022.101441_bib0027","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1186\/s12885-019-6324-7","article-title":"A gene expression-based study on immune cell subtypes and glioma prognosis","volume":"19","author":"Zhong","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tranon.2022.101441_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110873","article-title":"Tumor-infiltrating lymphocytes: warriors fight against tumors powerfully","volume":"132","author":"Lin","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.tranon.2022.101441_bib0029","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.1038\/s41598-018-24437-5","article-title":"Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma","volume":"8","author":"Rohr-Udilova","year":"2018","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.tranon.2022.101441_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaa311","article-title":"Clinical significance and immunogenomic landscape analyses of the immune cell signature based prognostic model for patients with breast cancer","volume":"22","author":"Wang","year":"2021","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.tranon.2022.101441_bib0031","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ebiom.2018.12.054","article-title":"Development and validation of an immune gene-set based prognostic signature in ovarian cancer","volume":"40","author":"Shen","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.tranon.2022.101441_bib0032","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5494858","article-title":"Identification and validation of immune-related gene prognostic signature for hepatocellular carcinoma","volume":"2020","author":"Chen","year":"2020","journal-title":"J. Immunol. Res."},{"issue":"9","key":"10.1016\/j.tranon.2022.101441_bib0033","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1136\/gutjnl-2020-320716","article-title":"Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma","volume":"70","author":"Shang","year":"2021","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.tranon.2022.101441_bib0034","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.tranon.2022.101441_bib0035","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1404214","article-title":"OX40 expression in hepatocellular carcinoma is associated with a distinct immune microenvironment, specific mutation signature, and poor prognosis","volume":"7","author":"Xie","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.tranon.2022.101441_bib0036","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/s12935-021-02108-2","article-title":"Identification and integrative analysis of ACLY and related gene panels associated with immune microenvironment reveal prognostic significance in hepatocellular carcinoma","volume":"21","author":"Xu","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"11","key":"10.1016\/j.tranon.2022.101441_bib0037","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s00262-012-1278-5","article-title":"B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence","volume":"61","author":"Sun","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.tranon.2022.101441_bib0038","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/ijc.21557","article-title":"Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas","volume":"118","author":"Luo","year":"2006","journal-title":"Int. J. Cancer"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523322001000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523322001000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:28:26Z","timestamp":1778833706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523322001000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":38,"alternative-id":["S1936523322001000"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2022.101441","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ALYREF associated with immune infiltration is a prognostic biomarker in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2022.101441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101441"}}